Arezzo A, Pagano N, Romeo F, Delconte G, Hervoso C, Morino M, Repici A
Center for Minimally Invasive Surgery, Università di Torino, Turin, Italy.
Surg Endosc. 2009 May;23(5):1065-9. doi: 10.1007/s00464-008-0133-4. Epub 2008 Oct 2.
Endoscopic mucosal resection (EMR) is today the treatment of choice for flat and sessile colorectal lesion, the only concern being completeness of resection. One of the major issues is the choice of the infiltrating substance to enable a long-lasting cushion under the lesion. The aim of this study was to prospectively evaluate safety and efficacy of hydroxy-propyl-methyl-cellulose (HPMC) injection for this purpose.
All flat and sessile lesions of the colon and rectum larger than 20 mm and considered suitable for EMR were included. In all cases 0.8% HPMC solution was injected through a 23G needle, in quantity according to the endoscopist's indication. Primary endpoints of the study were: (1) ability to perform en bloc resection of the lesions by using this new injection means, (2) complete resection rate, and (3) early and late complication rate.
We resected 27 flat, sessile, or laterally spreading lesions up to 60 mm (28 mm average). Mean dose of HPMC injected was 10.2 ml (range 8-40 ml). Median procedure time was 32 min (range 15-105 min). En bloc resection was achieved in up to 21 cases (78%). Histologically detected complete tumour removal was achieved in 23 lesions, whereas lateral margins could not be properly evaluated in 4 cases due to coagulation artefacts. No perforation was observed. Procedural spurting bleeding was managed by epinephrine injection in one case and clip application in the remaining. Two case of local recurrence of adenomatous tissue were observed at 3 and 12 months, and treated by EMR. No complication related to the use of HPMC was observed.
Injection of HPMC for EMR resulted safe and effective, allowing en bloc resection in the majority of cases with a limited number of complications. Continued progress in the field will include more outcomes research and techniques simplification.
内镜黏膜切除术(EMR)如今是扁平型和广基型结直肠病变的首选治疗方法,唯一需要关注的是切除的完整性。其中一个主要问题是选择浸润性物质,以便在病变下方形成持久的支撑垫。本研究的目的是前瞻性评估羟丙基甲基纤维素(HPMC)注射用于此目的的安全性和有效性。
纳入所有直径大于20mm且被认为适合EMR的结肠和直肠扁平型及广基型病变。在所有病例中,通过23G针头注射0.8%的HPMC溶液,注射量根据内镜医师的指示确定。本研究的主要终点为:(1)使用这种新的注射方法整块切除病变的能力;(2)完整切除率;(3)早期和晚期并发症发生率。
我们切除了27个扁平型、广基型或侧向扩散型病变,最大直径达60mm(平均28mm)。注射HPMC的平均剂量为10.2ml(范围8 - 40ml)。中位手术时间为32分钟(范围15 - 105分钟)。多达21例(78%)实现了整块切除。组织学检查发现23个病变实现了肿瘤完全切除,4例因凝血假象无法正确评估侧切缘。未观察到穿孔情况。术中1例喷射性出血通过肾上腺素注射处理,其余通过夹子夹闭处理。在3个月和12个月时观察到2例腺瘤组织局部复发,并通过EMR进行了治疗。未观察到与使用HPMC相关的并发症。
EMR注射HPMC安全有效,多数情况下可实现整块切除,并发症数量有限。该领域的持续进展将包括更多的结果研究和技术简化。